Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Somatic mutations lead to an oncogenic deletion of met in lung cancer.

Cancer research - 1 Jan 2006

Kong-Beltran Monica, Seshagiri Somasekar, Zha Jiping, Zhu Wenjing, Bhawe Kaumudi, Mendoza Nerissa, Holcomb Thomas, Pujara Kanan, Stinson Jeremy, Fu Ling, Severin Christophe, Rangell Linda, Schwall Ralph, Amler Lukas, Wickramasinghe Dineli, Yauch Robert

Abstract excerpt

Activating mutations in receptor tyrosine kinases play a critical role in oncogenesis. Despite evidence that Met kinase is deregulated in human cancer, the role of activating mutations in cancers other than renal papillary carcinoma has not been well defined. Here we report the identification of somatic intronic mutations of Met kinase that lead to an alternatively spliced transcript in lung cancer, which encodes...

Topics

Join the communities discussing this publication.

Alternative Splicing
Colonic Neoplasms
Mice, Nude
Mitogen-Activated Protein Kinases
Proto-Oncogene Proteins c-cbl

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Proto-Oncogene Proteins c-met

Receptors, Growth Factor

Source

Identifiers

PMID: 16397241
DOI: 10.1158/0008-5472.CAN-05-2749

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Somatic mutations lead to an oncogenic deletion of met in lung cancer.PMID 16397241Read ↗

Transforming properties of MET receptor exon 14 skipping can be recapitulated by loss of the CBL ubiquitin ligase binding site.Semantic proximity Read ↗

The promise of selective MET inhibitors in non-small cell lung cancer with MET exon 14 skippingSemantic proximity Read ↗

Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.Semantic proximity Read ↗

MET Activation in Lung Cancer and Response to Targeted TherapiesSemantic proximity Read ↗

Mechanistic insights into MET exon 14 skipping mutations and their role in tumor progression.Semantic proximity Read ↗

MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapySemantic proximity Read ↗

MET in human cancer: germline and somatic mutationsSemantic proximity Read ↗

Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.Semantic proximity Read ↗

Activating Point Mutations in the MET Kinase Domain Represent a Unique Molecular Subset of Lung Cancer and Other Malignancies Targetable with MET InhibitorsSemantic proximity Read ↗

MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-LifeSemantic proximity Read ↗

MET Exon 14 Mutation Encodes an Actionable Therapeutic Target in Lung Adenocarcinoma.Semantic proximity Read ↗

Recording and classifying MET receptor mutations in cancers.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.